The British Society for Haematology (BSH) has updated its guidelines for the management of people with post-transplant lymphoproliferative disorder (PTLD) after a solid organ transplant. They do not cover PTLD in people who have had a stem cell transplant.
PTLD refers to lymphoma that can develop in people who are taking medicines to dampen their immune system after a transplant. It is classified based on the type of lymphoma it looks like. PTLD is rare. Most people who have had transplants do not develop PTLD.
The updated guidelines cover diagnosis and staging, treatment recommendations and supportive care. They recommend that a medical team including transplant specialists, haematologists and radiation oncologists should be involved in developing a treatment plan.
Consultants and clinical scientists developed the guidelines based on the most up-to-date evidence from clinical trials. For more information on clinical trials for lymphoma, visit Lymphoma TrialsLink.
6 May 2021